{"id":66107,"date":"2026-05-24T11:15:20","date_gmt":"2026-05-24T03:15:20","guid":{"rendered":"https:\/\/flcube.com\/?p=66107"},"modified":"2026-05-24T11:15:21","modified_gmt":"2026-05-24T03:15:21","slug":"qyuns-therapeutics-and-huadong-medicine-secure-nmpa-approval-for-stelara-biosimilar-hdm3001-2-qx001s-in-crohns-disease","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66107","title":{"rendered":"Qyuns Therapeutics and Huadong Medicine Secure NMPA Approval for Stelara Biosimilar HDM3001-2\/QX001S in Crohn&#8217;s Disease"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Qyuns Therapeutics<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2509:HKG\">HKG: 2509<\/a>) announced that <strong>HDM3001-2\/QX001S<\/strong>, a <strong>biosimilar<\/strong> to Johnson &amp; Johnson&#8217;s autoimmune therapy <strong>Stelara (ustekinumab)<\/strong>, has received approval from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> for the treatment of <strong>Crohn&#8217;s disease<\/strong>. The drug was co-developed with Chinese pharmaceutical company <strong>Huadong Medicine Co., Ltd<\/strong> (SZ: 000963).<\/p>\n\n\n\n<h2 id=\"h-regulatory-approval-details\" class=\"wp-block-heading\">Regulatory Approval Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>National Medical Products Administration (NMPA), China<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>HDM3001-2\/QX001S (ustekinumab biosimilar)<\/td><\/tr><tr><td><strong>Reference Product<\/strong><\/td><td>Stelara (ustekinumab) by Johnson &amp; Johnson<\/td><\/tr><tr><td><strong>New Indication<\/strong><\/td><td>Crohn&#8217;s disease<\/td><\/tr><tr><td><strong>Previous Approvals<\/strong><\/td><td>Initial approval (October 2024), Pediatric plaque psoriasis (March 2025)<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>IL-12\/IL-23 inhibitor<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-development-partnership-amp-timeline\" class=\"wp-block-heading\">Development Partnership &amp; Timeline<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Collaboration Formation:<\/strong> <strong>Huadong Medicine<\/strong> and <strong>Qyuns Therapeutics<\/strong> established partnership in <strong>August 2020<\/strong> to develop HDM3001-2\/QX001S specifically for the Chinese market<\/li>\n\n\n\n<li><strong>Milestone Achievement:<\/strong> Became <strong>China&#8217;s first Stelara biosimilar<\/strong> upon initial approval in <strong>October 2024<\/strong><\/li>\n\n\n\n<li><strong>Regulatory Progression:<\/strong> Expanded to <strong>pediatric plaque psoriasis<\/strong> indication in <strong>March 2025<\/strong>, now adding <strong>Crohn&#8217;s disease<\/strong> as third approved indication<\/li>\n\n\n\n<li><strong>Strategic Significance:<\/strong> Represents growing domestic capability in complex biologic biosimilars for autoimmune conditions<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-commercial-outlook\" class=\"wp-block-heading\">Market Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Autoimmune Market Opportunity:<\/strong> China&#8217;s autoimmune disease market continues rapid expansion, with biologics representing the fastest-growing segment; ustekinumab biosimilars offer significant cost advantages over originator products<\/li>\n\n\n\n<li><strong>Pricing Advantage:<\/strong> Biosimilars typically launch at 30-70% discounts to reference products, potentially expanding access to premium biologic therapies for Chinese patients<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> HDM3001-2\/QX001S joins a growing pipeline of ustekinumab biosimilars globally, but maintains first-mover advantage in the Chinese market<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> With multiple indications now approved, the product addresses a broader patient population across dermatology and gastroenterology specialties, enhancing commercial viability<\/li>\n\n\n\n<li><strong>Healthcare System Benefits:<\/strong> Biosimilar adoption supports China&#8217;s healthcare cost containment initiatives while maintaining therapeutic efficacy standards<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, market adoption, and commercial expectations for HDM3001-2\/QX001S. Actual results may differ due to risks including market competition, pricing pressures, and evolving regulatory requirements.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026052101431_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026052101431_c.\"><\/object><a id=\"wp-block-file--media-9524533a-d6db-4c17-b9f3-440db45d047a\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026052101431_c.pdf\">2026052101431_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026052101431_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-9524533a-d6db-4c17-b9f3-440db45d047a\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Qyuns Therapeutics (HKG: 2509) announced that HDM3001-2\/QX001S, a biosimilar to Johnson &amp; Johnson&#8217;s autoimmune therapy&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[43,1239,114,149,15,495],"class_list":["post-66107","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-biosimilars","tag-hkg-2509","tag-huadong-medicine","tag-johnson-johnson","tag-product-approvals","tag-qyuns-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Qyuns Therapeutics and Huadong Medicine Secure NMPA Approval for Stelara Biosimilar HDM3001-2\/QX001S in Crohn&#039;s Disease - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Qyuns Therapeutics (HKG: 2509) announced that HDM3001-2\/QX001S, a biosimilar to Johnson &amp; Johnson&#039;s autoimmune therapy Stelara (ustekinumab), has received approval from China&#039;s National Medical Products Administration (NMPA) for the treatment of Crohn&#039;s disease. The drug was co-developed with Chinese pharmaceutical company Huadong Medicine Co., Ltd (SZ: 000963).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66107\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Qyuns Therapeutics and Huadong Medicine Secure NMPA Approval for Stelara Biosimilar HDM3001-2\/QX001S in Crohn&#039;s Disease\" \/>\n<meta property=\"og:description\" content=\"Qyuns Therapeutics (HKG: 2509) announced that HDM3001-2\/QX001S, a biosimilar to Johnson &amp; Johnson&#039;s autoimmune therapy Stelara (ustekinumab), has received approval from China&#039;s National Medical Products Administration (NMPA) for the treatment of Crohn&#039;s disease. The drug was co-developed with Chinese pharmaceutical company Huadong Medicine Co., Ltd (SZ: 000963).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66107\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-24T03:15:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-24T03:15:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66107#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66107\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Qyuns Therapeutics and Huadong Medicine Secure NMPA Approval for Stelara Biosimilar HDM3001-2\\\/QX001S in Crohn&#8217;s Disease\",\"datePublished\":\"2026-05-24T03:15:20+00:00\",\"dateModified\":\"2026-05-24T03:15:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66107\"},\"wordCount\":343,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biosimilars\",\"HKG: 2509\",\"Huadong Medicine\",\"Johnson &amp; Johnson\",\"Product approvals\",\"QYuns Therapeutics\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66107#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66107\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66107\",\"name\":\"Qyuns Therapeutics and Huadong Medicine Secure NMPA Approval for Stelara Biosimilar HDM3001-2\\\/QX001S in Crohn's Disease - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-24T03:15:20+00:00\",\"dateModified\":\"2026-05-24T03:15:21+00:00\",\"description\":\"Qyuns Therapeutics (HKG: 2509) announced that HDM3001-2\\\/QX001S, a biosimilar to Johnson & Johnson's autoimmune therapy Stelara (ustekinumab), has received approval from China's National Medical Products Administration (NMPA) for the treatment of Crohn's disease. The drug was co-developed with Chinese pharmaceutical company Huadong Medicine Co., Ltd (SZ: 000963).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66107#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66107\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66107#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Qyuns Therapeutics and Huadong Medicine Secure NMPA Approval for Stelara Biosimilar HDM3001-2\\\/QX001S in Crohn&#8217;s Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Qyuns Therapeutics and Huadong Medicine Secure NMPA Approval for Stelara Biosimilar HDM3001-2\/QX001S in Crohn's Disease - Insight, China&#039;s Pharmaceutical Industry","description":"Qyuns Therapeutics (HKG: 2509) announced that HDM3001-2\/QX001S, a biosimilar to Johnson & Johnson's autoimmune therapy Stelara (ustekinumab), has received approval from China's National Medical Products Administration (NMPA) for the treatment of Crohn's disease. The drug was co-developed with Chinese pharmaceutical company Huadong Medicine Co., Ltd (SZ: 000963).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66107","og_locale":"en_US","og_type":"article","og_title":"Qyuns Therapeutics and Huadong Medicine Secure NMPA Approval for Stelara Biosimilar HDM3001-2\/QX001S in Crohn's Disease","og_description":"Qyuns Therapeutics (HKG: 2509) announced that HDM3001-2\/QX001S, a biosimilar to Johnson & Johnson's autoimmune therapy Stelara (ustekinumab), has received approval from China's National Medical Products Administration (NMPA) for the treatment of Crohn's disease. The drug was co-developed with Chinese pharmaceutical company Huadong Medicine Co., Ltd (SZ: 000963).","og_url":"https:\/\/flcube.com\/?p=66107","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-24T03:15:20+00:00","article_modified_time":"2026-05-24T03:15:21+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66107#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66107"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Qyuns Therapeutics and Huadong Medicine Secure NMPA Approval for Stelara Biosimilar HDM3001-2\/QX001S in Crohn&#8217;s Disease","datePublished":"2026-05-24T03:15:20+00:00","dateModified":"2026-05-24T03:15:21+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66107"},"wordCount":343,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biosimilars","HKG: 2509","Huadong Medicine","Johnson &amp; Johnson","Product approvals","QYuns Therapeutics"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66107#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66107","url":"https:\/\/flcube.com\/?p=66107","name":"Qyuns Therapeutics and Huadong Medicine Secure NMPA Approval for Stelara Biosimilar HDM3001-2\/QX001S in Crohn's Disease - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-24T03:15:20+00:00","dateModified":"2026-05-24T03:15:21+00:00","description":"Qyuns Therapeutics (HKG: 2509) announced that HDM3001-2\/QX001S, a biosimilar to Johnson & Johnson's autoimmune therapy Stelara (ustekinumab), has received approval from China's National Medical Products Administration (NMPA) for the treatment of Crohn's disease. The drug was co-developed with Chinese pharmaceutical company Huadong Medicine Co., Ltd (SZ: 000963).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66107#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66107"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66107#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Qyuns Therapeutics and Huadong Medicine Secure NMPA Approval for Stelara Biosimilar HDM3001-2\/QX001S in Crohn&#8217;s Disease"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66107","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66107"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66107\/revisions"}],"predecessor-version":[{"id":66109,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66107\/revisions\/66109"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66107"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66107"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66107"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}